Division of Hematology-Oncology, Department of Medicine, Stony Brook School of Medicine, Stony Brook, NY, USA.
Northport VA Medical Center, Northport, NY, USA.
Adv Exp Med Biol. 2020;1273:135-145. doi: 10.1007/978-3-030-49270-0_7.
Hematopoietic stem cells (HSCs) rely on instructive cues from the marrow microenvironment for their maintenance and function. Accumulating evidence indicates that the survival and proliferation of hematopoietic neoplasms are dependent not only on cell-intrinsic, genetic mutations, and other molecular alterations present within neoplastic stem cells, but also on the ability of the surrounding microenvironmental cells to nurture and promote the malignancy. It is anticipated that a better understanding of the molecular and cellular events responsible for these microenvironmental features of neoplastic hematopoiesis will lead to improved treatment for patients. This review will focus on the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), in which an acquired signaling kinase mutation (JAK2V617F) plays a central, pathogenetic role in 50-100% of patients with these disorders. Evidence is presented that the development of an MPN requires both an abnormal, mutation-bearing (i.e., neoplastic) HSC and an abnormal, mutation-bearing microenvironment.
造血干细胞 (HSCs) 依赖于骨髓微环境中的指导线索来维持和发挥功能。越来越多的证据表明,造血肿瘤的存活和增殖不仅依赖于肿瘤干细胞中存在的细胞内在的遗传突变和其他分子改变,还依赖于周围微环境细胞滋养和促进恶性肿瘤的能力。预计,更好地了解导致这些肿瘤性造血的微环境特征的分子和细胞事件,将为患者提供更好的治疗。本综述将重点介绍骨髓增殖性肿瘤 (MPNs)、真性红细胞增多症 (PV)、特发性血小板增多症 (ET) 和原发性骨髓纤维化 (PMF),在这些疾病中,获得性信号激酶突变 (JAK2V617F) 在 50-100%的患者中发挥着核心的致病作用。有证据表明,MPN 的发展既需要异常的、携带突变的(即肿瘤性的)HSC,也需要异常的、携带突变的微环境。